Circulating tumor DNA: from discovery to clinical application in breast cancer

Xu, Jiachi; Gao, Hongyu; Guan, Xinyu; Meng, Jiahao; Ding, Shirong; Long, Qian; Yi, Wenjun

doi:10.3389/fimmu.2024.1355887

Cited by 5 publications

(1 citation statement)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor type and stage: Different types and stages of cancer can vary in the shedding of ctDNA into circulation. Advanced-stage cancers with higher tumor burdens tend to release more ctDNA compared to early-stage cancers [ 44 – 46 ].…”

Section: Triggers Of Communication Between Cells In Gtmentioning

confidence: 99%

Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization

Puvvula,

Johnson,

Bernal-Mizrachi

2024

Oncoscience

View full text Add to dashboard Cite

Section: Triggers Of Communication Between Cells In Gtmentioning

confidence: 99%

Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization

Puvvula,

Johnson,

Bernal-Mizrachi

2024

Oncoscience

View full text Add to dashboard Cite

Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy

Raei,

Heydari,

Tabarestani

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Estrogen receptors express in nearly 70% of breast cancers (ER-positive). Estrogen receptor alpha plays a fundamental role as a significant factor in breast cancer progression for the early selection of therapeutic approaches. Accordingly, there has been a surge of attention to non-invasive techniques, including circulating Cell-free DNA (ccfDNA) or Cell-Free DNA (cfDNA), to detect and track ESR1 genotype. Therefore, this study aimed to examine the diagnosis accuracy of ESR1 mutation detection by cell-free DNA in breast cancer patientsthrough a systematic review and comprehensive meta-analysis. Methods PubMed, Embase, and Web of Science databases were searched up to 6 April 2022. Diagnostic studies on ESR1 measurement by cfDNA, which was confirmed using the tumour tissue biopsy, have been included in the study. The sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were considered to analyse the data. Results Out of 649 papers, 13 papers with 15 cohorts, including 389 participants, entered the meta-analyses. The comprehensive meta-analysis indicated a high sensitivity (75.52, 95% CI 60.19–90.85), specificity (88.20, 95% CI 80.99–95.40), and high accuracy of 88.96 (95% CI 83.23–94.69) for plasma ESR1. We also found a moderate PPV of 56.94 (95% CI 41.70–72.18) but a high NPV of 88.53 (95% CI 82.61–94.44). We also found an NLR of 0.443 (95% CI 0.09–0.79) and PLR of 1.60 (95% CI 1.20–1.99). Conclusion This systematic review and comprehensive meta-analysis reveal that plasma cfDNA testing exhibits high sensitivity and specificity in detecting ESR1 mutations in breast cancer patients. This suggests that the test could be a valuable diagnostic tool. It may serve as a dependable and non-invasive technique for identifying ESR1 mutations in breast cancer patients. However, more extensive research is needed to confirm its prognostic value.

show abstract

Interleukin signaling in the regulation of natural killer cells biology in breast cancer

Xu,

Gao,

Azhar

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

In the field of breast cancer treatment, the immunotherapy involving natural killer (NK) cells is increasingly highlighting its distinct potential and significance. Members of the interleukin (IL) family play pivotal regulatory roles in the growth, differentiation, survival, and apoptosis of NK cells, and are central to their anti-tumor activity. These cytokines enhance the ability of NK cells to recognize and eliminate tumor cells by binding to specific receptors and activating downstream signaling pathways. Furthermore, interleukins do not function in isolation; the synergistic or antagonistic interactions between different interleukins can drive NK cells toward various functional pathways, ultimately leading to diverse outcomes for breast cancer patients. This paper reviews the intricate relationship between NK cells and interleukins, particularly within the breast cancer tumor microenvironment. Additionally, we summarize the latest clinical studies and advancements in NK cell therapy for breast cancer, along with the potential applications of interleukin signaling in these therapies. In conclusion, this article underscores the critical role of NK cells and interleukin signaling in breast cancer treatment, providing valuable insights and a significant reference for future research and clinical practice.

show abstract

Circulating tumor DNA: from discovery to clinical application in breast cancer

Cited by 5 publications

References 124 publications

Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization

Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization

Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy

Interleukin signaling in the regulation of natural killer cells biology in breast cancer

Contact Info

Product

Resources

About